Business Context and Reporting Period
This Form 8-K is a current report filed by Tocagen Inc. on February 12, 2019. The filing addresses Item 5.02 regarding the approval of executive compensation for fiscal year 2019 and the payment of 2018 incentive cash bonuses. Note: The request metadata references "Forte Biosciences, Inc.," but the filing text explicitly identifies the registrant as Tocagen Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
| Executive Officer | Title | 2019 Base Salary | 2019 Target Bonus (% of Base) | 2018 Cash Bonus Paid |
|---|---|---|---|---|
| Martin J. Duvall | Chief Executive Officer | $515,000 | 50% | $270,932 |
| Mark Foletta | Executive Vice President, Chief Financial Officer | $390,000 | 40% | $160,688 |
The 2019 base salary increases are effective as of March 1, 2019.
Material Changes
The filing details the approval of salary increases and target bonus percentages for the named executive officers for fiscal year 2019 compared to prior arrangements. Additionally, it confirms the disbursement of 2018 incentive cash bonuses based on corporate and individual performance assessments.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The 2018 bonus payments were determined based on an assessment of corporate and individual performance during 2018.
Investor Verification Checklist
- Verify the registrant name is Tocagen Inc., not Forte Biosciences, Inc.
- Confirm the effective date of the 2019 salary increases is March 1, 2019.
- Review the Annual Incentive Plan to understand the specific performance metrics used to calculate the 2018 cash bonuses.
- Check subsequent filings for the actual payout of the 2019 target bonuses.